Emgality Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to high migraine prevalence rates, unmet needs in chronic migraine care, clinical success of cgrp targeting, neurologist adoption of biologics, improved diagnostic awareness.

The growth in the forecast period can be attributed to growth in chronic migraine population, expansion into new headache indications, increasing biologic drug acceptance, improved patient adherence, rising neurology healthcare spending. Major trends in the forecast period include rising adoption of cgrp inhibitors, shift toward preventive migraine therapies, growing demand for long term headache control, expansion of biologic neurology treatments, patient preference for monthly injections.

The rising prevalence of migraine is expected to drive the growth of the emgality market in the coming years. Migraine is a neurological disorder characterized by severe, throbbing headaches, often accompanied by symptoms such as nausea, light and sound sensitivity, and sometimes visual or sensory disturbances known as auras. The increasing incidence of migraines is linked to factors such as higher stress levels, lifestyle changes, environmental triggers, and greater awareness and diagnosis of the condition. Emgality works by blocking the calcitonin gene-related peptide (CGRP), reducing both the frequency and intensity of migraine attacks. This treatment provides long-term relief, improving quality of life and reducing migraine-related disability for frequent sufferers. For example, in May 2023, Migraine Canada, a Canada-based organization supporting individuals affected by migraines, reported that migraines impact 12% of Canadians (approximately 4.5 million) and over 1 billion people globally. The prevalence is higher in women, with a 30% lifetime incidence, compared to 8% in men and 10% in children. One in four households is affected, with 1-2% experiencing chronic migraines. Therefore, the increasing prevalence of migraine is supporting the growth of the emgality market.

A key trend in the emgality market is the adoption of strategic partnerships to enhance technology integration and expand market reach. Strategic partnerships involve collaboration between two or more organizations to combine resources, expertise, and efforts to achieve shared objectives. For instance, in December 2023, Organon & Co., a US-based healthcare company focused on women's health, expanded its partnership with Eli Lilly to broaden access to migraine treatments, including Emgality and RAYVOW, across Europe. Organon leverages its expertise in central nervous system disorders and established commercial capabilities, while Lilly maintains manufacturing and marketing authorization. The partnership targets the significant impact of migraines on women and strengthens Organon's portfolio in women's health, ensuring effective delivery of these treatments.

In January 2023, AffaMed Therapeutics, a China-based clinical-stage biopharmaceutical company, partnered with Eli Lilly and Company to introduce Galcanezumab in China as a preventive treatment for episodic migraine. The collaboration addresses critical medical needs, enhances patients’ quality of life, and strengthens AffaMed's neurology portfolio and market presence. Eli Lilly, a US-based pharmaceutical company, manufactures emgality.

Major companies operating in the emgality market are Eli Lilly and Company.

North America was the largest region in the emgality market in 2025. The regions covered in the emgality market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the emgality market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the emgality market by increasing costs related to biologic manufacturing inputs and temperature sensitive distribution networks. Neurology treatment segments in north america and europe are most impacted due to reliance on imported monoclonal antibodies. These tariffs may increase therapy costs for clinics and hospital pharmacies. At the same time, tariffs are driving investments in localized biologics manufacturing and enhancing supply chain security for migraine treatments.

The emgality market research report is one of a series of new reports that provides emgality market statistics, including emgality industry global market size, regional shares, competitors with a emgality market share, detailed emgality market segments, market trends and opportunities, and any further data you may need to thrive in the emgality industry. This emgality market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Emgality is a prescription medication used to prevent migraines and treat episodic cluster headaches in adults. It is a monoclonal antibody that targets and blocks calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks and pain pathways.

The primary clinical indications for emgality are migraine prevention and cluster headaches. Migraine prevention aims to reduce the frequency and severity of migraine episodes through CGRP blockers, lifestyle modifications, and prophylactic medications. The medication is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by hospitals, clinics, ambulatory care facilities, and home care settings.

The emgality market consists of sales of injections, prefilled syringes, and auto-injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.